Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded at Baird R W

Baird R W upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) to a strong-buy rating in a research report sent to investors on Monday,Zacks.com reports.

A number of other research firms have also issued reports on CPRX. StockNews.com lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. Bank of America reissued a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. HC Wainwright lifted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Truist Financial increased their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Finally, Stephens began coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective for the company. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $32.25.

Catalyst Pharmaceuticals Stock Up 1.3 %

NASDAQ CPRX opened at $23.40 on Monday. Catalyst Pharmaceuticals has a fifty-two week low of $13.12 and a fifty-two week high of $24.64. The business has a fifty day moving average of $22.05 and a 200-day moving average of $20.85. The stock has a market cap of $2.79 billion, a price-to-earnings ratio of 19.83, a price-to-earnings-growth ratio of 2.25 and a beta of 0.80.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the sale, the insider now owns 51,391 shares of the company’s stock, valued at $1,167,603.52. The trade was a 18.93 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares during the period. nVerses Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter worth about $50,000. Larson Financial Group LLC boosted its position in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $65,000. Finally, KBC Group NV raised its holdings in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,542 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.